Dihydroxyacetone phosphate accumulation leads to podocyte pyroptosis in diabetic kidney disease.
Zongwei ZhangHongtu HuQiang LuoKeju YangZhengping ZouMing ShiWei LiangPublished in: Journal of cellular and molecular medicine (2023)
Diabetic kidney disease (DKD) can lead to accumulation of glucose upstream metabolites due to dysfunctional glycolysis. But the effects of accumulated glycolysis metabolites on podocytes in DKD remain unknown. The present study examined the effect of dihydroxyacetone phosphate (DHAP) on high glucose induced podocyte pyroptosis. By metabolomics, levels of DHAP, GAP, glucose-6-phosphate and fructose 1, 6-bisphosphate were significantly increased in glomeruli of db/db mice. Furthermore, the expression of LDHA and PKM2 were decreased. mRNA sequencing showed upregulation of pyroptosis-related genes (Nlrp3, Casp1, etc.). Targeted metabolomics demonstrated higher level of DHAP in HG-treated podocytes. In vitro, ALDOB expression in HG-treated podocytes was significantly increased. siALDOB-transfected podocytes showed less DHAP level, mTORC1 activation, reactive oxygen species (ROS) production, and pyroptosis, while overexpression of ALDOB had opposite effects. Furthermore, GAP had no effect on mTORC1 activation, and mTORC1 inhibitor rapamycin alleviated ROS production and pyroptosis in HG-stimulated podocytes. Our findings demonstrate that DHAP represents a critical metabolic product for pyroptosis in HG-stimulated podocytes through regulation of mTORC1 pathway. In addition, the results provide evidence that podocyte injury in DKD may be treated by reducing DHAP.
Keyphrases
- high glucose
- nlrp inflammasome
- endothelial cells
- reactive oxygen species
- poor prognosis
- fluorescent probe
- type diabetes
- mass spectrometry
- ms ms
- cell proliferation
- dna damage
- living cells
- cell death
- blood glucose
- diabetic nephropathy
- long non coding rna
- wound healing
- skeletal muscle
- signaling pathway
- blood pressure
- cancer therapy
- transcription factor
- single cell
- drug delivery
- glycemic control